TMCnet News
Xcovery to Present at the 7th Annual Biotech Showcase Conference in San Francisco on Jan. 12Xcovery, a group of privately held clinical stage companies focused on the development of next-generation targeted therapeutics for cancer and ophthalmology, today announced it will present a company update at the 7th Annual Biotech Showcase conference in San Francisco. The presentation is at the Parc 55 Wyndham hotel on Jan.12, 2015, at 11:30 a.m. PST in the Hearst room. Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Biotech Showcase is produced by Demy Colton Life Science Advisors and EBD Group. About Xcovery Xcovery, which is comprised of two companies, Xcovery Holding Company, LLC, and Tyrogenex, Inc., is focused on the development of next-generation targeted therapeutics for cancer and ophthalmology. Founded in 2006 by Executive Chairman Sheridan Snyder, a veteran entrepreneur who founded Genzyme, in partnership with Chief Scientific Officer Chris Liang, Ph.D., co-developer of Sutent®, Pfizer's first small molecule oncology drug. Xcovery has developed a comprehensive pipeline of new therapies with higher potency and lower toxicity that target a wide range of important disease indications Xcovery Holding Company, LLC, is developing X-396, a small molecule ALK inhibitor, for treatment of ALK-positive NSCLC, lymphoma and neuroblastoma. Xcovery is enrolling patients in the expansion cohort portion of a Phase 1/2 study of X-396 for the treatment of non-small cell lung cancer where ALK is deregulated with plans to begin a Phase 3 registration study in 2015. Tyrogenex is a privately held company focused on developing X-82, an orally administered, dual VEGFR/PDGFR inhibitor, as a targeted therapeutic for solid tumors and ophthalmological diseases, respectively. In the first half of 2015, Tyrogenex will begin a Phase 2 study evaluating the safety and preliminary biologic activity/efficacy of X-82 in patients with wet age-related macular degeneration (AMD (News - Alert)).
|
